Oncolytics Biotech Files 6-K
Ticker: ONCY · Form: 6-K · Filed: Nov 19, 2025 · CIK: 1129928
Sentiment: neutral
Topics: reporting, administrative
Related Tickers: ONCY
TL;DR
ONCOLYTICS BIOTECH INC filed a 6-K on Nov 19, 2025, confirming its foreign private issuer status and US principal office.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on November 19, 2025, reporting as a foreign private issuer. The filing indicates the company's principal executive offices are located at 4350 Executive Drive, Suite 325, San Diego, CA 92121, and that it files annual reports under Form 20-F.
Why It Matters
This filing provides an update on Oncolytics Biotech Inc.'s reporting status and administrative information, which is important for investors tracking the company's regulatory compliance.
Risk Assessment
Risk Level: low — This filing is a routine administrative update and does not contain significant financial or operational news.
Key Players & Entities
- Oncolytics Biotech Inc. (company) — Registrant
- November 19, 2025 (date) — Filing Date
- 4350 Executive Drive, Suite 325 San Diego, CA 92121 (location) — Principal Executive Offices
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Filing
FAQ
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is November 19, 2025.
What is the name of the company filing this report?
The company filing this report is Oncolytics Biotech Inc.
Where are Oncolytics Biotech Inc.'s principal executive offices located?
Oncolytics Biotech Inc.'s principal executive offices are located at 4350 Executive Drive, Suite 325, San Diego, CA 92121.
Under which form does the registrant file its annual reports?
The registrant files its annual reports under Form 20-F.
What type of issuer is Oncolytics Biotech Inc. for SEC reporting purposes?
Oncolytics Biotech Inc. is reporting as a Foreign Private Issuer.
Filing Stats: 332 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2025-11-19 09:02:40
Filing Documents
- form6kfdapdac.htm (6-K) — 17KB
- fdapdac.htm (EX-99.1) — 14KB
- 0001129928-25-000091.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date November 19, 2025 Kirk Look Chief Financial Officer